INVA Stock: Price, Earnings History and SEC Filings
Innoviva, Inc. (INVA) last traded at $21.22, down 0.42% on the latest session and up 0.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.59 against an analyst estimate of $0.56, a beat of 5.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
INVA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.59 | $0.56 | +5.36% |
| Mar 2026 | May 6, 2026 | $0.44 | $0.43 | +2.33% |
| Dec 2025 | Feb 25, 2026 | $1.94 | $0.34 | +470.59% |
| Sep 2025 | Nov 5, 2025 | $1.08 | $0.46 | +134.78% |
INVA beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How INVA reacts to earnings
Across its last 8 earnings releases, INVA moved 3.0% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +2.93% |
| 2026-05-06 | After close | +1.24% |
| 2026-02-25 | After close | -2.89% |
| 2025-11-05 | After close | +12.89% |
| 2025-08-06 | After close | +1.15% |
| 2025-05-07 | After close | -0.85% |
| 2025-02-26 | After close | -1.96% |
| 2024-11-06 | After close | +0.40% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
INVA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $411M | – | $196M | – | $3.30 |
| 2024 | $359M | – | $188M | – | $0.36 |
| 2023 | $310M | – | $141M | – | $2.20 |
| 2022 | $331M | – | $202M | – | $2.37 |
| 2021 | $392M | – | $364M | – | $2.87 |
| 2020 | $337M | – | $313M | – | $2.02 |
| 2019 | $261M | – | $257M | – | $1.43 |
| 2018 | $261M | – | $224M | – | $3.53 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for INVA
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · May 18, 2026Officer or director change, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 4, 2026Shareholder vote
- DEF 14A · Mar 24, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
- 10-K · Feb 25, 2026
- 10-Q · Nov 5, 2025
Insider filing activity
INVA insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
INVA news
- AbbVie (ABBV) Tops Q3 Earnings and Revenue EstimatesOct 30, 2026 · finance.yahoo.com
- Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026Oct 19, 2026 · finance.yahoo.com
About Innoviva, Inc.
Innoviva, Inc. (INVA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.